The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

In Figaro-DKD, in which 7,437 participants were given Kerendia once daily or placebo when added to standard of care, 10.8% of those who received Kerendia had hyperkalemia-related events as opposed ...

The FDA approval of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia, Bayer) for reducing risks for kidney and heart complications for adults with CKD associated ...

This morning, the German group revealed that mineralocorticoid receptor antagonist (MRA) Kerendia (finerenone) was able to reduce cardiovascular death and other heart failure events compared to ...

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). FINEARTS-HF is a randomised, double-blind, placebo-controlled, multicentre, event-driven Phase III trial to assess ...

The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the ...

KERENDIA is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and ...